Clinical Scorecard: Molecular Insights into Severe Traumatic Brain Injury in Children: Integrated Omics Identify Potential Therapeutic Targets

At a Glance

Key Highlights

• Severe pediatric TBI involves acute and subacute phases with ongoing secondary brain injury mechanisms.
• Integrated multi-omics (whole blood transcriptomics and serum metabolomics) over three timepoints provides novel molecular insights.
• No current therapeutic interventions have proven efficacy in large clinical trials despite promising preclinical data.

Guideline-Based Recommendations

Diagnosis

• Use clinical severity scores such as Glasgow Coma Scale (GCS ≤ 8) to define severe TBI.
• Employ protein biomarkers (e.g., S100B, neuron-specific enolase, glial fibrillary acidic protein) for diagnostic and prognostic assessment.
• Incorporate neuroimaging and clinical data for comprehensive injury characterization.

Management

• Provide mechanical ventilation and intensive care support in PICU for severe pediatric TBI patients.
• Recognize the therapeutic window during secondary brain injury phases for potential interventions.
• Currently, no validated pharmacologic therapies exist; management remains supportive.

Monitoring & Follow-up

• Collect serial blood samples at acute (within 24 and 36–60 hours) and subacute (around day 9) phases for biomarker and molecular profiling.
• Monitor clinical severity scores and neuroimaging findings longitudinally.
• Use integrated omics data to potentially guide future personalized therapeutic strategies.

Risks

• Secondary brain injury processes may continue for days to years post-injury, contributing to chronic disabilities.
• Exclusion of patients with significant comorbidities, pregnancy, or non-accidental trauma is important for accurate assessment.
• Long-term cognitive, behavioral, and physical disabilities are common sequelae.

Patient & Prescribing Data

Children and adolescents aged 1 to 21 years with severe TBI requiring mechanical ventilation in PICU

No current pharmacologic treatments have demonstrated efficacy; integrated omics approaches may identify future therapeutic targets.

Clinical Best Practices

• Early identification and classification of severe TBI using GCS and clinical criteria.
• Utilize multi-omics approaches to understand molecular mechanisms and identify biomarkers.
• Collect and analyze blood samples at defined acute and subacute timepoints to monitor secondary injury progression.
• Maintain supportive intensive care management focusing on ventilation and stabilization.
• Exclude confounding factors such as non-accidental trauma and significant comorbidities in clinical studies.

References

• Epidemiology and impact of pediatric TBI
• Protein biomarkers in TBI
• Integrated omics methodology in pediatric TBI